Register online | Log in | My Prescrire

Issue contents

• Current issue
• Last 12 issues
• All issues

Topics

• Annual Prescrire Awards
• Advancing healthcare policy
• Positions
• Mediator° - the criminal trial
• Drugs to avoid: 2021 update
• Spotlight

About Prescrire

• Who are we?
• How we work
• AMP: non-profit
• Financing
• "Non merci"
• Where to find us
• About Prescrire International
• Testimonials
• Prescrire events
• A global network

Offers

• Subscribe now
• Solidarity Subscription Rate
• Subscribers: register online
• Prescrire's other products
• Free Special Edition
• Sign up to receive the newsletter

Prescrire's other websites

In Prescrire's Spotlight

Oral semaglutide (Rybelsus°): more uncertainty than with subcutaneous liraglutide FEATURED REVIEW Semaglutide was first authorised in the European Union as a solution for weekly subcutaneous injections. It was authorised more recently in oral tablet form. How do Prescrire's editors rate this new product? Full review (3 pages) available for download by subscribers. 1 June 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ In the June issue of Prescrire International: Non-metastatic, castration-resistant prostate cancer FREE DOWNLOAD Survival extended with the addition of apalutamide or enzalutamide. Full text available for free download. 1 June 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Covid-19 drugs and vaccines: big money and winning alliances  Editorial   The market for covid-19 drugs and vaccines is huge, involving billions of patients, with tens of billions of dollars potentially up for grabs. Business as usual? Not quite. 1 June 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Covid-19 : Follow Prescrire's independent, evidence-based analysis of the pandemic  COVID-19  Prescrire's editors are publishing an ongoing series of news updates featuring independent analysis of developments related to the covid-19 pandemic. Useful and practical information, to help healthcare professionals gain a clear and balanced view. 1 June 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Iodine during pregnancy: supplementation should not be systematic Iodine-containing food supplements have no proven benefits for pregnant women, and can be dangerous for the unborn child. 1 June 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Oral cancer drugs: care provided in community pharmacies Community pharmacists in France can offer, and claim payment for, structured pharmaceutical care for the growing number of patients taking oral cancer drugs. 1 June 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Memantine (Ebixa° and other brands): perception disorders Memantine is a drug with psychotropic actions, misuse of which can become problematic, leading, in particular, to dissociative disorders which are not always effects being sought by the user. 1 June 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Pre-exposure prophylaxis for HIV (PrEP): reduction in risk of infection confirmed For patients at high risk of infection by the HIV virus, evaluation has confirmed the efficacy of PrEP using a combination of emtricitabine + tenofovir disoproxil (Truvada° and other brands). 1 June 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Prescrire: independence and transparency, in the name of better patient care The independent French medical journal Prescrire is produced by healthcare professionals who strive to protect medical information and continuing education from the contradictory influences at play in the medico-pharmaceutical arena. 1 June 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Waste in covid-19 clinical trials  Outlook  The covid-19 pandemic has given rise to a large number of clinical trials evaluating a wide range of therapeutic avenues, but not all are worthwhile. 1 June 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ "Cutting the Cord: Curtailing Commercial Influence on Healthcare" a conference to be held online, 16-18 June 2021 Organised by the US-based non-profit group PharmedOut, the conference will address commercial influence on healthcare, focussing on how its damaging effects can be mitigated. 1 June 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ France's Mediator° trial: Servier and the French drug regulatory agency convicted and sentenced A Paris court ruled that the company Servier and its former second-in-command were guilty of "aggravated deception with endangerment to life" and "involuntary bodily harm and manslaughter" for having concealed the true properties of Mediator° (benfluorex). > Read more in our special section "Mediator° - the criminal trial" 1 June 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Enjoy these features, and more, in our upcoming issues COMING SOON Solriamfetol and drowsiness due to narcolepsy or sleep apnoea • Tezacaftor + ivacaftor and cystic fibrosis • Limiting the use of proton-pump inhibitors • Human papillomavirus vaccine in men • Dietary supplements: poorly evaluated and poorly monitored... > Subscribe now 1 June 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Revision of the EU's general pharmaceutical legislation in 2022: Prescrire's remarks on the European Commission Roadmap (4/2021)  ADVANCING HEALTHCARE POLICY  Prescrire highlights the need for high standards of assessment for pharmaceuticals, calling for comparative trial data to be included in the marketing authorisation application. Accelerated assessment procedures should be limited to exceptional situations. Prescrire also points out several areas that are missing from the roadmap. 27 April 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ "Top Texts of 2020", from the editors of Prescrire International  FREE SPECIAL EDITION  Check out this brand new sampling of texts from Prescrire International, a wholly independent monthly journal written by and for healthcare professionals. Inside, top articles from our "New Products", "Adverse Effects" and "Reviews" sections, plus our annual update of drugs to avoid. > Click here for your free copy 1 March 2021

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Follow Prescrire International on Facebook and Twitter Keep up with the latest from Prescrire's editors, and support our values of independence and quality information, first and foremost in the interest of patients. Click here to > Follow us on Facebook or > Follow us on Twitter 1 November 2020

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Subscribe today for full access to top-quality content from Prescrire International Subscribe now Enjoy access to subscriber-only content available on our website, including every article published in Prescrire International since 1992. Prices for a one-year subscription start at 150 euros (less for students and residents of lower-income countries). 1 November 2020

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Receive the free, monthly "Independent Drug & Healthcare Newsletter" Click here to sign up for the free Newsletter from the editors of the non-profit journal Prescrire International, with highlights of the contents of the latest issue. 1 November 2020

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Drugs to avoid, in the name of better patient care   DRUGS TO AVOID - 2021 UPDATE  Independent French medical journal Prescrire has published its annual update of drugs to avoid. The goal is to make it easier to choose high-quality care, and to prevent disproportionate harm to patients. > Read more

¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ Read more All the subjects in Prescrire's Spotlight >

• Sitemap |
• Terms of use |
• Contact
• |Top of page